Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 12:3:1295902.
doi: 10.3389/fopht.2023.1295902. eCollection 2023.

Emerging therapies in the medical management of thyroid eye disease

Alisha Kamboj  1 , Andrew R Harrison  1   2 , Ali Mokhtarzadeh  1
Affiliations
Review

Emerging therapies in the medical management of thyroid eye disease

Alisha Kamboj et al. Front Ophthalmol (Lausanne). .

Abstract

Introduction: Thyroid eye disease (TED) is an immune-mediated disorder associated with a heterogenous array of manifestations that may unfavorably impact vision and quality of life. As understanding of this entity's complex pathogenesis has evolved, so have therapies with novel molecular targets offering promise for improved patient outcomes.

Results: Emerging immunologic therapies for the management of thyroid eye disease have diverse mechanisms of actions and routes of administration. Different conventional and biological immunosuppressive agents have been studied as mediators of the autoimmune and autoinflammatory pathways in thyroid eye disease. Teprotumumab - an anti-IGF-1R monoclonal antibody that has recently emerged as a first-line therapy for active, moderate-to-severe TED - has demonstrated statistically significant improvements in proptosis, diplopia, clinical activity score, and quality of life compared to placebo. Currently under investigation are several other agents, with varying administration modalities, that aim to inhibit IGF-1R: VRDN-001 (intravenous), VRDN-002 or VRDN-003 (subcutaneous), lonigutamab (subcutaneous), and linsitinib (oral). Tocilizumab, a monoclonal antibody of interleukin 6, has played a role in the management of multiple autoimmune and inflammatory conditions and may offer promise in TED. Another incipient biologic target for TED management is the neonatal Fc receptor, inhibition of which has potential to decrease recycling of immunoglobulin and antibody levels; agents addressing this target including monoclonal antibodies as well as antibody fragments. Finally, hypolipidemic agents may play a role as mediators of TED-associated inflammation.

Conclusion: Among the agents under investigation that aim to decrease ocular morbidity associated with TED are agents that IGF-1R, interleukin 6, and the neonatal Fc receptor. The management of TED continues to expand with novel immunologic approaches for disease therapy.

Keywords: Graves’ disease (GD); IGF-1R; neonatal Fc receptor (FcRn); teprotumumab; thyroid eye disease (TED); thyroid orbitopathy.

PubMed Disclaimer

Conflict of interest statement

Author AH was a speaker and consultant of Horizon Pharmaceuticals and RVL Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med (2016) 375(16):1552–65. doi: 10.1056/NEJMra1510030 - DOI - PubMed
    1. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, et al. . Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol (1996) 121(3):284–90. doi: 10.1016/S0002-9394(14)70276-4 - DOI - PubMed
    1. Barbesino G, Salvi M, Freitag SK. Future Projections in Thyroid Eye Disease. J Clin Endocrinol Metab (2022) 107(Suppl 1):S47. doi: 10.1210/CLINEM/DGAC252 - DOI - PMC - PubMed
    1. Yoon J, Kikkawa D. Thyroid eye disease: From pathogenesis to targeted therapies. Taiwan J Ophthalmol (2022) 12(1):3. doi: 10.4103/TJO.TJO_51_21 - DOI - PMC - PubMed
    1. Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol (2021) 13. doi: 10.1177/25158414211027760 - DOI - PMC - PubMed

LinkOut - more resources